Physician profile
Dalyn Tate
NPI 1962281469
$523.56
in general payments reported to CMS, 2019-2025
13 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.89 · 2024: $127 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $94.95 | 2023-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $70.31 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $63.40 | 2023-2025 | |
| Lilly USA, LLC | $56.23 | 2024-2025 | Zepbound, Mounjaro |
| Ars Pharmaceuticals Operations, INC. | $52.38 | 2025 | Neffy |
| Alkermes, INC. | $34.57 | 2025 | Vivitrol |
| Abbott Laboratories | $32.42 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.93 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $22.67 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $21.17 | 2024 | |
| Exact Sciences Corporation | $18.19 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $16.60 | 2025 | Shingrix |
| Esperion Therapeutics, INC. | $14.74 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalyn Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.